Although it is estimated that 19,500 Australian men will be diagnosed with prostate cancer in 2019, results from a clinical trial are bringing fresh hope to patients.
At the American Society of Clinical Oncology (ASCO) annual international conference in Chicago in June, Professor Lisa Horvath, Director of Medical Oncology and Research at Chris O’Brien Lifehouse, alongside a team of researchers, released ground-breaking results that take us one step closer to finding more effective treatment for prostate cancer.
Professor Horvath and her colleagues presented the results of their phase three clinical trial for a drug called Enzalutamide, which prevents the cancer cells in patients with metastatic prostate cancer from using testosterone to grow. The research team found that adding Enzalutamide to current treatments (eg. testosterone suppressing therapy) has the capacity to slow cancer growth and increase overall survival of patients by 33%. These results could give hope to the thousands of men who are diagnosed with prostate cancer every year.
Congratulations to Professor Lisa Horvath and her team at the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) for this exciting new discovery in metastatic prostate cancer treatment.